Maria Francisca Ham

6PUBLICATIONS
12CO-AUTHORS
Haematological tumoursImmunogenetics (incl. genetic immunology)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 01, 2025
Different Immunohistochemical Expression of CTLA-4 in Diffuse Large B-Cell Lymphoma and Its Associated Prognostic Factors.

Liyona Rifani, Maria Francisca Ham, Dina Khoirunnisa

|Nov 07, 2024
Fifteen Years of Non-Hodgkin Lymphoma in an Indonesian National Referral Hospital: Epidemiologic Trends and Diagnostic Challenges.

Agnes Stephanie Harahap, Maria Francisca Ham, Andree Kurniawan

|Dec 30, 2022
Association of Programmed Death-Ligand 1 Expression with Aggressive Histological Types of Thyroid Carcinoma.

Agnes Stephanie Harahap, Fanny Kamarudy Lay, Ria Kodariah

|Jun 09, 2022
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.

Wulyo Rajabto, Vitya Chandika, Agnes Stephanie Harahap

|Mar 08, 2022
MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP.

Cosphiadi Irawan, Martha Iskandar, Agnes Stephanie Harahap

|Jan 21, 2022
Clinicopathological Profile of Thyroid Carcinoma in Young Patients: An Indonesian Single-Center Study.

Agnes Stephanie Harahap, Desty Gusti Sari, Marini Stephanie

Pageof 1